All eyes are on emergence of second biosimilar

Industry officials say that the second biosimilar will be available in the first half of this year as Celltrion won approval to produce the world’s first antibody biosimilar, Resima in July 2012.

Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis.

Korean conglomerates such as Hanwha Group and Samsung Group are starting to dev...